GlycoNex Announces Japanese Regulatory Submission for Denosumab Biosimilar SPD8
The Quick Take
Regulatory decision in Japan anticipated as early as the end of 2027, subject to PMDA review; GlycoNex continues to seek partners for markets outside Japan NEW TAIPEI CITY, Nov. 8, 2026 /PRNewswire/ -- GlycoNex, Inc. (TPEx: 4168), a clinical-stage biotechnology company developing...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Small businesses hit with Aus Post underpaid postage fees despite photographic evidence - Yahoo Finance Australia
Small businesses hit with Aus Post underpaid postage fees despite photographic evidence Yahoo Finance Australia
Business
OceanFirst Financial director Nicos Katsoulis buys $178,277 in stock
Local
Yordenis Ugás announces his new profession in the United States: "Always a Cuban, decent and hard-working." - CiberCuba
Yordenis Ugás announces his new profession in the United States: "Always a Cuban, decent and hard-working." CiberCuba
Local
Yordenis Ugás Embraces Real Estate Career in the U.S.: "Forever a Cuban, Decent and Hardworking" - CubaHeadlines
Yordenis Ugás Embraces Real Estate Career in the U.S.: "Forever a Cuban, Decent and Hardworking" CubaHeadlines